Inhibrx Reports Third Quarter 2026 Financial Results
Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Third Quarter 2026 Financial Results San Diego, CA, November 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in
How this was made
The 30-second read
Why it matters
The earnings release highlights a widening loss and minimal revenue, which may prompt short‑term selling, but the sizable cash balance and upcoming data could attract long‑term interest.
Market read
Primary earnings disclosure for a Nasdaq‑listed biotech; relevance driven by financial loss, cash position, and pending trial readouts.
What to watch
The upcoming Phase 2/3 readouts for ozekibart and ordastobart could catalyze a rebound despite the current loss.
Background
The SEC Form 8‑K provides the first public disclosure of Inhibrx's third‑quarter 2026 results, including clinical trial milestones and financial metrics.
Ticker impact
Inhibrx Biosciences reported its Q3 2026 financial results, including $2.0 M revenue, $199.5 M cash and a $38.7 M net loss.
downward pressure as investors digest the widening loss and limited revenue
The company posted a larger net loss versus the prior year and only $2 M of revenue, while cash remains ample but no positive earnings surprise.
Market effects
Biotech sector may see modest pullback as a small‑cap clinical‑stage firm reports a loss.
Limited to U.S. and Nasdaq‑listed biotech investors.
Low; the filing does not affect broader market indices.
Counterpoint
Cash runway of $199 M could support upcoming trial readouts, offering upside if data exceed expectations.
Key entities
- companyInhibrx Biosciences, Inc.
Clinical‑stage biopharma reporting Q3 2026 results.
